Free Trial

EyePoint Pharmaceuticals (EYPT) Short Interest Ratio & Short Volume

$10.71
-0.04 (-0.37%)
(As of 05/31/2024 ET)

EyePoint Pharmaceuticals Short Interest Data

Current Short Interest
8,130,000 shares
Previous Short Interest
6,600,000 shares
Change Vs. Previous Month
+23.18%
Dollar Volume Sold Short
$105.20 million
Short Interest Ratio
7.0 Days to Cover
Last Record Date
May 15, 2024
Outstanding Shares
52,084,000 shares
Percentage of Shares Shorted
15.61%
Today's Trading Volume
1,109,590 shares
Average Trading Volume
1,474,693 shares
Today's Volume Vs. Average
75%
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling EyePoint Pharmaceuticals ?

Sign up to receive the latest short interest report for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

EYPT Short Interest Over Time

EYPT Days to Cover Over Time

EYPT Percentage of Float Shorted Over Time

EyePoint Pharmaceuticals Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
5/15/20248,130,000 shares $105.20 million +23.2%N/A7 $12.94
4/30/20246,600,000 shares $116.16 million +0.9%N/A5.6 $17.60
4/15/20246,540,000 shares $139.17 million -4.5%N/A6.7 $21.28
3/31/20246,850,000 shares $141.59 million +4.1%N/A7.1 $20.67
3/15/20246,580,000 shares $141.34 million +15.0%N/A6.4 $21.48
2/29/20245,720,000 shares $155.64 million +20.4%N/A4.5 $27.21
2/15/20244,750,000 shares $138.13 million -7.6%N/A2.9 $29.08
1/31/20245,140,000 shares $138.42 million -1.2%N/A3.3 $26.93
1/15/20245,200,000 shares $118.35 million -2.4%N/A3.5 $22.76
12/31/20235,330,000 shares $123.18 million +12.2%N/A3.9 $23.11
12/15/20234,750,000 shares $92.86 million -32.2%N/A3.6 $19.55
11/30/20237,010,000 shares $43.81 million +28.9%25.0%5.9 $6.25
11/15/20235,440,000 shares $36.39 million +1.7%19.4%10.3 $6.69
10/31/20235,350,000 shares $32.21 million +9.0%19.2%10.3 $6.02
10/15/20234,910,000 shares $39.77 million -29.3%17.6%9.3 $8.10
9/30/20236,940,000 shares $55.45 million +12.3%25.1%11.6 $7.99
9/15/20236,180,000 shares $64.77 million +9.2%22.3%10.2 $10.48
8/31/20235,660,000 shares $56.09 million +12.1%20.6%9.5 $9.91
8/15/20235,050,000 shares $71.66 million +3.7%18.8%8.9 $14.19
7/31/20234,870,000 shares $60.88 million +1.9%N/A9.3 $12.50
7/15/20234,780,000 shares $52.44 million -7.7%N/A4.9 $10.97
6/30/20235,180,000 shares $45.07 million +7.5%N/A5.6 $8.70
6/15/20234,820,000 shares $32.73 million +13.2%18.4%5.3 $6.79
5/31/20234,260,000 shares $25.77 million +5.2%16.2%4.8 $6.05
5/15/20234,050,000 shares $24.30 million +11.3%15.4%4.7 $6.00
4/30/20233,640,000 shares $22.86 million -0.3%14.1%4.4 $6.28
4/15/20233,650,000 shares $15.80 million +9.3%14.2%5.3 $4.33
3/31/20233,340,000 shares $9.82 million +19.7%13.0%11 $2.94
3/15/20232,790,000 shares $6.67 million +34.8%10.9%10 $2.39
2/28/20232,070,000 shares $6.91 million No Change8.1%8.1 $3.34
2/15/20232,070,000 shares $7.66 million -4.2%8.1%8.5 $3.70
1/31/20232,160,000 shares $10.07 million +6.9%8.6%9.3 $4.66
1/15/20232,020,000 shares $10.18 million +13.5%8.0%9.4 $5.04
12/30/20221,780,000 shares $6.23 million +6.0%7.1%12.3 $3.50
12/15/20221,680,000 shares $4.50 million -2.9%6.7%11.6 $2.68
11/30/20221,730,000 shares $5.54 million -3.4%6.9%13.6 $3.20
11/15/20221,790,000 shares $7.91 million -9.1%7.1%14.1 $4.42
10/31/20221,970,000 shares $10.64 million -1.5%N/A16.1 $5.40
10/15/20222,000,000 shares $11.20 million -1.5%7.7%14.3 $5.60
9/30/20222,030,000 shares $16.06 million -0.5%7.8%12.5 $7.91
Trump conviction scandal exposed (Ad)

In this new documentary, you’ll discover the truth about Trump’s criminal conviction, who’s really pulling the puppet strings, and why this is just phase one in their dark plan to reshape America. It’s not just about blocking Trump’s re-election…

To get all the details, go here now.
9/15/20222,040,000 shares $16.30 million +0.5%7.9%12.7 $7.99
8/31/20222,030,000 shares $20.30 million +1.5%7.8%12.7 $10.00
8/15/20222,000,000 shares $22.24 million -8.3%7.7%12.8 $11.12
7/31/20222,180,000 shares $19.90 million +7.4%8.3%13.8 $9.13
7/15/20222,030,000 shares $20.12 million +1.0%7.8%14.4 $9.91
6/30/20222,010,000 shares $15.82 million +2.0%7.7%16.8 $7.87
6/15/20221,970,000 shares $15.62 million -5.3%7.5%16.7 $7.93
5/31/20222,080,000 shares $20.07 million -3.3%8.0%16 $9.65
5/15/20222,150,000 shares $21.26 million -1.4%8.2%14.1 $9.89
4/30/20222,180,000 shares $24.63 million +0.5%8.3%13.4 $11.30
4/15/20222,170,000 shares $27.54 million +0.5%8.3%11.9 $12.69
3/31/20222,160,000 shares $26.24 million +4.9%8.3%9.6 $12.15
3/15/20222,060,000 shares $24.82 million +3.0%7.9%7.9 $12.05
2/28/20222,000,000 shares $19.90 million +3.6%7.7%7.2 $9.95
2/15/20221,930,000 shares $19.59 million -2.5%7.4%6.6 $10.15
1/31/20221,980,000 shares $18.55 million -8.3%7.6%2.4 $9.37
1/15/20222,160,000 shares $21.45 million +11.3%N/A2.7 $9.93
12/31/20211,940,000 shares $23.75 million +0.5%7.4%2.5 $12.24
12/15/20211,930,000 shares $28.27 million -3.5%7.4%2.6 $14.65
11/30/20212,000,000 shares $31.60 million +98.0%8.1%2.9 $15.80
11/15/20211,010,000 shares $14.44 million -34.0%4.2%1.5 $14.30
10/29/20211,530,000 shares $17.55 million +10.9%7.3%11 $11.47
10/15/20211,380,000 shares $15.79 million +0.7%6.6%12.1 $11.44
9/30/20211,370,000 shares $14.28 million -3.5%6.5%11.3 $10.42
9/15/20211,420,000 shares $14.31 million +2.9%6.8%8.4 $10.08
8/31/20211,380,000 shares $15.10 million +4.6%6.6%8.2 $10.94
8/13/20211,320,000 shares $13.66 million -4.4%6.3%8 $10.35
7/30/20211,380,000 shares $11.34 million +5.3%6.6%8.1 $8.22
7/15/20211,310,000 shares $10.00 million +0.8%6.3%7 $7.63
6/30/20211,300,000 shares $11.69 million +14.0%6.2%6.6 $8.99
6/15/20211,140,000 shares $10.84 million -10.2%5.5%6.7 $9.51
5/28/20211,270,000 shares $12.48 million +3.3%6.1%6.6 $9.83
5/14/20211,230,000 shares $10.90 million +116.3%5.9%5.2 $8.86
4/30/2021568,700 shares $6.13 million +1.5%2.7%2.1 $10.78
4/15/2021560,300 shares $5.47 million -15.2%2.6%1.7 $9.77
3/31/2021660,700 shares $6.40 million +28.1%3.2%1.9 $9.69
3/15/2021515,600 shares $5.78 million +35.1%2.5%1.3 $11.21
2/26/2021381,700 shares $4.21 million +9.0%2.2%1 $11.03
2/12/2021350,200 shares $4.74 million +38.6%2.2%1 $13.54
1/29/2021252,600 shares $2.77 million -5.9%1.8%0.8 $10.96
1/15/2021268,500 shares $2.94 million +19.6%3.0%1.2 $10.95
12/31/2020224,500 shares $1.32 million -35.6%2.2%1 $5.90
12/15/2020348,800 shares $1.58 million -83.3%3.5%2.1 $4.53
11/30/20202,090,000 shares $11.27 million -11.8%20.8%14.5 $5.39
11/15/20202,370,000 shares $10.59 million +0.4%2.4%1.8 $4.47
10/30/20202,360,000 shares $9.13 million +15.7%2.6%0.9 $3.87
10/15/20202,040,000 shares $10.27 million -7.3%2.3%0.8 $5.03
9/30/20202,200,000 shares $11.40 million +3.8%2.6%0.9 $5.18
9/15/20202,120,000 shares $11.44 million -4.1%2.6%0.9 $5.40
8/31/20202,210,000 shares $11.83 million +14.5%2.7%0.9 $5.35
Trump conviction scandal exposed (Ad)

In this new documentary, you’ll discover the truth about Trump’s criminal conviction, who’s really pulling the puppet strings, and why this is just phase one in their dark plan to reshape America. It’s not just about blocking Trump’s re-election…

To get all the details, go here now.
8/14/20201,930,000 shares $11.77 million -3.0%2.4%0.8 $6.10
7/31/20201,990,000 shares $14.13 million -8.7%2.4%2.2 $7.10
7/15/20202,180,000 shares $15.59 million -18.7%2.7%2.5 $7.15
6/30/20202,680,000 shares $20.38 million -40.4%3.3%3.1 $7.60
6/15/20204,500,000 shares $37.71 million +57.9%5.5%5.8 $8.38
5/29/20202,850,000 shares $24.51 million -9.2%3.5%4.9 $8.60
5/15/20203,140,000 shares $25.12 million +7.9%3.8%4.9 $8.00
4/30/20202,910,000 shares $28.17 million +3.2%3.6%3.9 $9.68
4/15/20202,820,000 shares $25.38 million -8.4%3.5%3.4 $9.00
3/31/20203,080,000 shares $2.65 million -21.9%3.8%3.6 $0.86
3/13/20203,942,800 shares $3.19 million -6.1%4.8%4.1 $0.81
2/28/20204,200,000 shares $3.86 million -44.1%5.2%5.8 $0.92
2/14/20207,510,000 shares $7.89 million -6.5%10.0%11.5 $1.05
1/31/20208,030,000 shares $10.84 million -4.7%12.3%13.3 $1.35
1/15/20208,430,000 shares $16.19 million -0.7%12.9%13.8 $1.92
12/31/20198,490,000 shares $16.39 million -5.5%13.0%14.9 $1.93
8/15/20195,963,300 shares $8.53 million +5.4%12.5%14.4 $1.43

EYPT Short Interest - Frequently Asked Questions

What is EyePoint Pharmaceuticals' current short interest?

Short interest is the volume of EyePoint Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of May 15th, traders have sold 8,130,000 shares of EYPT short. Learn More on EyePoint Pharmaceuticals' current short interest.

What is a good short interest ratio for EyePoint Pharmaceuticals?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. EYPT shares currently have a short interest ratio of 7.0. Learn More on EyePoint Pharmaceuticals's short interest ratio.

Which institutional investors are shorting EyePoint Pharmaceuticals?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of EyePoint Pharmaceuticals: Ikarian Capital LLC, Torno Capital LLC, and Affinity Asset Advisors LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Is EyePoint Pharmaceuticals' short interest increasing or decreasing?

EyePoint Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 8,130,000 shares, an increase of 23.2% from the previous total of 6,600,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does EyePoint Pharmaceuticals' short interest compare to its competitors?

Here is how the short interest of companies compare to EyePoint Pharmaceuticals: Standard BioTools Inc. (3.27%), Cytek Biosciences, Inc. (5.52%), Quanterix Co. (3.10%), Pacific Biosciences of California, Inc. (20.77%), Nautilus Biotechnology, Inc. (1.47%), Harvard Bioscience, Inc. (1.43%), Seer, Inc. (6.74%), Akoya Biosciences, Inc. (5.26%), Bionano Genomics, Inc. (7.51%), Prenetics Global Limited (1.15%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks.

What does it mean to sell short EyePoint Pharmaceuticals stock?

Short selling EYPT is an investing strategy that aims to generate trading profit from EyePoint Pharmaceuticals as its price is falling. EYPT shares are trading down $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against EyePoint Pharmaceuticals?

A short squeeze for EyePoint Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of EYPT, which in turn drives the price of the stock up even further.

How often is EyePoint Pharmaceuticals' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including EYPT, twice per month. The most recent reporting period available is May, 15 2024.



More Short Interest Resources from MarketBeat

This page (NASDAQ:EYPT) was last updated on 6/1/2024 by MarketBeat.com Staff

From Our Partners